Stocktoria
NutriBand Inc. NTRB
NutriBand Inc. (NTRB) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2026 revenue was $2.0M at a -404.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.73 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.557 |
| Retained earnings / assets | -6.186 |
| EBIT / assets | -1.102 |
| Equity / liabilities | 7.691 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NTRB | NutriBand Inc. | 3/9 | -15.84 | — | — |
| AVR | Anteris Technologies Global Corp. | 2/9 | — | — | — |
| CLGN | CollPlant Biotechnologies Ltd | 3/9 | — | — | — |
| FEED | ENvue Medical, Inc. | 2/9 | -6.2 | — | — |
| SPAI | Safe Pro Group Inc. | 4/9 | 9.05 | — | — |
| COCH | Envoy Medical, Inc. | 2/9 | — | — | — |
| CUPR | Cuprina Holdings (Cayman) LTD | 4/9 | -2.57 | — | — |
About NutriBand Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
FAQ
Is NTRB financially healthy?
NutriBand Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NTRB pay a dividend?
No, NutriBand Inc. does not currently pay a dividend.
How profitable is NTRB?
In FY2026, NutriBand Inc. had a net margin of -404.1% and a return on equity of -123.2%.
What is the analyst price target for NTRB?
The average Wall-Street price target for NutriBand Inc. is $15.00, about 387.8% above the recent price, from 1 analysts.
Is NTRB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NutriBand Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-01-31. Facts plus Stocktoria's own computed scores — not investment advice.